Teachers Advisors LLC Purchases 25,225 Shares of Bruker Corporation (NASDAQ:BRKR)
Teachers Advisors LLC boosted its position in shares of Bruker Corporation (NASDAQ:BRKR) by 20.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 148,229 shares of the medical research company’s stock after buying an additional 25,225 shares during the period. Teachers Advisors LLC’s holdings in Bruker Corporation were worth $3,458,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in BRKR. Canada Pension Plan Investment Board raised its position in shares of Bruker Corporation by 648.9% in the first quarter. Canada Pension Plan Investment Board now owns 70,400 shares of the medical research company’s stock worth $1,642,000 after buying an additional 61,000 shares during the last quarter. Parametrica Management Ltd purchased a new position in shares of Bruker Corporation during the first quarter worth approximately $309,000. Denver Investment Advisors LLC raised its position in shares of Bruker Corporation by 7.2% in the first quarter. Denver Investment Advisors LLC now owns 22,215 shares of the medical research company’s stock worth $518,000 after buying an additional 1,500 shares during the last quarter. Quadrature Capital Ltd purchased a new position in shares of Bruker Corporation during the fourth quarter worth approximately $244,000. Finally, Keybank National Association OH raised its position in shares of Bruker Corporation by 10.2% in the first quarter. Keybank National Association OH now owns 49,466 shares of the medical research company’s stock worth $1,154,000 after buying an additional 4,592 shares during the last quarter. Hedge funds and other institutional investors own 67.00% of the company’s stock.
Shares of Bruker Corporation (NASDAQ BRKR) traded up 2.29% during mid-day trading on Friday, reaching $27.69. The company had a trading volume of 55,610 shares. The firm has a market capitalization of $4.42 billion, a price-to-earnings ratio of 27.61 and a beta of 1.10. The stock has a 50 day moving average of $28.63 and a 200-day moving average of $25.63. Bruker Corporation has a one year low of $19.59 and a one year high of $30.22.
Bruker Corporation (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.23 EPS for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.03. The business had revenue of $414.90 million for the quarter, compared to analysts’ expectations of $384.75 million. Bruker Corporation had a net margin of 9.65% and a return on equity of 27.18%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.20 earnings per share. Equities analysts predict that Bruker Corporation will post $1.12 EPS for the current year.
Bruker Corporation announced that its Board of Directors has approved a share buyback plan on Friday, May 12th that permits the company to buyback $225.00 million in outstanding shares. This buyback authorization permits the medical research company to buy shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its stock is undervalued.
BRKR has been the topic of a number of recent research reports. Deutsche Bank AG increased their price objective on Bruker Corporation from $25.00 to $27.00 and gave the company a “hold” rating in a research report on Monday, May 15th. Barclays PLC reiterated an “equal weight” rating and issued a $30.00 price objective (up from $26.00) on shares of Bruker Corporation in a research report on Monday, July 17th. Cowen and Company reiterated a “hold” rating and issued a $29.00 price objective on shares of Bruker Corporation in a research report on Friday, July 14th. BidaskClub lowered Bruker Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Cleveland Research raised Bruker Corporation from a “neutral” rating to a “buy” rating in a research note on Thursday, April 27th. One analyst has rated the stock with a sell rating, nine have given a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $27.00.
In other Bruker Corporation news, Director Richard Kniss sold 24,000 shares of the company’s stock in a transaction on Tuesday, June 13th. The shares were sold at an average price of $28.23, for a total transaction of $677,520.00. Following the sale, the director now owns 46,753 shares of the company’s stock, valued at $1,319,837.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Frank H. Laukien purchased 73,000 shares of the business’s stock in a transaction on Thursday, May 18th. The shares were purchased at an average cost of $26.22 per share, for a total transaction of $1,914,060.00. Following the transaction, the chief executive officer now directly owns 37,750,851 shares of the company’s stock, valued at approximately $989,827,313.22. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 80,455 shares of company stock worth $2,111,321 and have sold 117,624 shares worth $3,271,574. Corporate insiders own 35.20% of the company’s stock.
Bruker Corporation Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR).
Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.